Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00949117 · OUTCOME

Difference Between Measures of Weight at Baseline and at Week 24

Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
kilograms
Interval / dispersion
Standard Deviation
Time frame
24 weeks

What was measured

Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period.

Groups in this outcome

Arm I- Cyproheptadine Hydrochloride

Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.

Arm II Cyproheptadine HCl and PediaSure or Ensure

Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I- Cyproheptadine Hydrochloride1
Arm II Cyproheptadine HCl and PediaSure or Ensure0

Reported measurements

Source class 1
Values in kilograms · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Arm I- Cyproheptadine Hydrochloride4.3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4.3
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period.
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
    id
    OG000
    title
    Arm I- Cyproheptadine Hydrochloride
  2. description
    Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
    id
    OG001
    title
    Arm II Cyproheptadine HCl and PediaSure or Ensure
param Type
MEAN
reporting Status
POSTED
time Frame
24 weeks
title
Difference Between Measures of Weight at Baseline and at Week 24
type
PRIMARY
unit Of Measure
kilograms

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice